May 9, 2013
Mitsubishi Tanabe Pharma Corporation’s (MTPC) sales rose 3.0% from a year earlier to 419,179 million yen in FY2013 (ended March 2013), helped by increased income from technology licensing fees such as royalties from the multiple sclerosis treatment Gilenya (fingolimod) licensed...read more